CSIMarket Company Name, Ticker, Suppliers, else..
 
Prime Medicine Inc   (NASDAQ: PRME)
Other Ticker:  
 
 
Price: $1.2650 $0.04 2.846%
Day's High: $1.2899 Week Perf: -4.89 %
Day's Low: $ 1.24 30 Day Perf: -36.75 %
Volume (M): 45 52 Wk High: $ 8.27
Volume (M$): $ 56 52 Wk Avg: $3.98
Open: $1.24 52 Wk Low: $1.12



 Market Capitalization (Millions $) 150
 Shares Outstanding (Millions) 119
 Employees 49
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -392
 Cash Flow (TTM) (Millions $) 141
 Capital Exp. (TTM) (Millions $) 7

Prime Medicine Inc
Prime Medicine Inc is a biotechnology company that specializes in developing gene editing therapies to treat genetic diseases. Their mission is to provide innovative solutions using CRISPR technology to correct disease-causing genetic mutations. Prime Medicine Inc aims to revolutionize the field of gene therapy by developing safe and effective treatments for a wide range of genetic disorders, with a particular focus on diseases with limited treatment options. They are committed to advancing the field of precision medicine and improving the quality of life for patients affected by genetic diseases.


   Company Address: 60 First Street Cambridge 2141 MA
   Company Phone Number: 465-0013   Stock Exchange / Ticker: NASDAQ PRME


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BEAM        5.56% 
CRSP        11.64% 
EDIT        17.39% 
MRNA   -1.61%    
NVAX   -5.33%    
STRO   -7.71%    
• View Complete Report
   



Product Service News

Prime Medicines Advancements in Genetic Editing Highlight New Potential for Treating Wilsons Disease,

Published Tue, Oct 15 2024 12:01 PM UTC

Prime Medicine s Pioneering Approach to Wilson s Disease: A Step Toward Transformative Genetic Therapies In a significant announcement that underscores the potential for revolutionary advancements in genetic therapies, Prime Medicine Inc., a biotechnology firm listed on Nasdaq with the ticker PRME, has revealed plans to showcase new, compelling preclinical data for Wilson s ...
Partnership

Prime Medicine and Bristol Myers Squibb Form Strategic Alliance to Accelerate Advanced T-Cell Therapies

Published Mon, Sep 30 2024 11:00 AM UTC

Prime Medicine, a biotechnology company specializing in gene editing technologies, has announced a strategic research collaboration and licensing agreement with Bristol Myers Squibb (BMS), a leading biopharmaceutical firm. This partnership aims to develop and commercialize a range of innovative T-cell therapies that utilize Prime Medicine s cutting-edge gene editing capabili...
Management Announcement

Prime Medicine Charts a New Course in Genetic Medicine: Innovative Strategies and Strong Financial Performance Pave the Path Ahead,

Published Mon, Sep 30 2024 11:01 AM UTC

Prime Medicine s Strategic Advancements in Genetic MedicinePrime Medicine Inc. is making waves in the biotechnology sector with its innovative approach to genetic medicine, capitalizing on its prime editing platform to establish a strategically focused pipeline. With an emphasis on high-value programs in core therapeutic areas, the company aims to set a strong foothold in t...
Prime Medicine Inc

Prime Medicine Inc.: Navigating Rough Waters Amidst Stock Market Turmoil


Understanding the Decline of Prime Medicine Inc Stock
In the ever-evolving biotechnology and pharmaceuticals sector, companies' share prices can significantly fluctuate based on various performance metrics and market perceptions. One company that has recently captured attention is Prime Medicine Inc. (Nasdaq: PRME), which has faced a challenging year marked by a substantial decline in its stock price. As of late 2023, Prime Medicine Inc.'s stock has decreased by 64.14% compared to the previous year, while showing a decline of 17.88% during the third quarter of 2024. With its current trading price sitting just 9.5% above its 52-week low, it is essential to delve into the reasons behind this downturn and the company?s financial performance.


Financial Analysis of Prime Medicine Inc.
Stocks on the Move

title Exsilio Pioneering Genetic Medicine with Revolutionary mRNA and Lipid Nanoparticle Delivery

Published Fri, Jun 28 2024 5:25 AM UTC

Exsilio Debuts with $82M, Propelling Genetic Medicine ForwardIn a groundbreaking move, Exsilio, a biotech company, has recently made its debut in the field of genetic medicine. With a promising approach, the company aims to overcome some of the limitations in the field by delivering medicines via messenger RNA (mRNA) and lipid nanoparticles. This innovative technology has th...






Prime Medicine Inc's Segments

  Prime Medicine Inc Outlook

On April 23 2024 the Prime Medicine Inc provided following guidance

Prime Medicine Inc. has recently announced that they will be presenting new preclinical data at upcoming scientific meetings to showcase the broad potential of their Prime Editing technology. This includes data for PM359, which demonstrates the ability of Prime Editors to efficiently, reproducibly, and durably correct the causative mutation of CGD (Chronic Granulomatous Disease). This development is a significant milestone for the company as they are on track to enter clinical development in 2024, with initial data expected to be released in 2025.

In addition to this exciting announcement, Prime Medicine Co-Founder, David Liu, Ph.D., has been awarded the ASGCT Outstanding Achievement Award, highlighti...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com